RxPG News Feed for RxPG News

Medical Research Health Special Topics World
 Asian Health
 Food & Nutrition
 Men's Health
 Mental Health
 Occupational Health
 Public Health
 Sleep Hygiene
 Women's Health
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 World Healthcare
   Latest Research
 Alternative Medicine
  Clinical Trials
  Myocardial Infarction
 Clinical Trials
 Infectious Diseases
 Sports Medicine
   Medical News
 Awards & Prizes
   Special Topics
 Odd Medical News

Last Updated: Oct 11, 2012 - 10:22:56 PM
Myocardial Infarction Channel

subscribe to Myocardial Infarction newsletter
Latest Research : Cardiology : Myocardial Infarction

   EMAIL   |   PRINT
Drug-Eluting Stents Effective in Acute Myocardial Infarction: STRATEGY trial

May 4, 2005 - 5:42:00 PM
"In conclusion, our study provides proof of concept for a new treatment strategy in STEMI that incorporates unrestricted use of sirolimus-eluting stenting but results in no (European market) or only a modest (U.S. market) increase in medical expenditure"

[RxPG] A type of coronary artery stent that releases a medication appears to result in better outcomes than traditional stents for heart attack patients, according to a study in the May 4 issue of JAMA.

Sirolimus, a substance that is thought to help prevent reclosure of coronary arteries, can be released from certain types of stents (metal devices inserted to keep a coronary artery open after angioplasty) to greatly reduce the need for target-vessel revascularization (TVR) compared with bare-metal stents (i.e., stents without medication), according to background information in the article. These drug-eluting stents have the potential to further improve long-term clinical outcome after primary percutaneous coronary intervention (PCI), such as angioplasty. However, the lack of randomized trials to assess the safety and long-term efficacy of sirolimus-eluting stent implantation in patients with acute ST-segment elevation (a certain measurement on an electrocardiogram) myocardial infarction (STEMI), in conjunction with the expected financial consequences, currently limit use of sirolimus-eluting stents in this setting. Current clinical guidelines specifically recommend the drug abciximab during primary PCI. At current European list prices, the use of the drug tirofiban instead of abciximab would absorb the difference in cost between stenting with sirolimus-eluting vs. bare-metal stents.

Marco Valgimigli, M.D., of the University of Ferrara, Italy and colleagues compared angiographic and clinical outcomes for the treatments of high-dose tirofiban plus sirolimus-eluting stenting vs. a current preferred strategy for STEMI treatment, pretreatment with abciximab plus bare-metal stenting. The STRATEGY trial included 175 patients presenting to a single referral center in Italy with STEMI or presumed new left bundle-branch block between March 6, 2003 and April 23, 2004. Patients received either tirofiban regimen plus sirolimus-eluting stenting (n = 87) or abciximab plus bare-metal stenting (n = 88).

The researchers found that 14 of 74 patients (19 percent) in the tirofiban plus sirolimus-eluting stent group and 37 of 74 patients (50 percent) in the abciximab plus bare-metal stent group reached the primary end point (death, nonfatal heart attack, stroke, or binary restenosis [narrowing of artery] at 8 months). The cumulative incidence of death, reinfarction, stroke, or TVR was significantly lower in the tirofiban plus sirolimus-eluting stent group (18 percent) vs. the abciximab plus bare-metal stent group (32 percent), predominantly reflecting a reduction in the need for TVR. Binary restenosis was present in 6 of 67 (9 percent) and 24 of 66 (36 percent) patients in the tirofiban plus sirolimus-eluting stent and abciximab plus bare-metal stent groups, respectively.

"In conclusion, our study provides proof of concept for a new treatment strategy in STEMI that incorporates unrestricted use of sirolimus-eluting stenting but results in no (European market) or only a modest (U.S. market) increase in medical expenditure," the authors write.

Publication: JAMA. 2005;293:2109-2117
On the web: www.jamamedia.org 

Advertise in this space for $10 per month. Contact us today.

Related Myocardial Infarction News
Therapeutic Hypothermia - Cooling therapy protects brain after cardiac arrest
Height loss may increase heart attack risk
Few athletes survive sudden cardiac arrest (SCA)
PlGF involved in Post Myocardial Infarction Healing Process
The key elements for success in the rapid treatment of heart attacks
Daily cocoa intake can save you from heart attack
Heartbreaks can trigger heart attacks in the healthy
Chronic noise exposure increase risk of heart attacks
Sweat is good indicator of impending heart attack
Darbepoietin offers significant protection to heart tissue from injury due to ischemia

Subscribe to Myocardial Infarction Newsletter

Enter your email address:

 Additional information about the news article
For funding/support and financial disclosure information, please see the JAMA article

In an accompanying editorial, Mauricio G. Cohen, M.D., and E. Magnus Ohman, M.D., of the University of North Carolina, Chapel Hill, discuss the findings of the STRATEGY trial.

"… the STRATEGY trial is an important step in exploring the use of drug-eluting stents in the setting of AMI. The data suggesting that the use of drug-eluting stents in AMI may be superior to the traditional bare-metal stent approach are encouraging. However, the focus should now shift to the long-term prevention of thrombotic complications through appropriate long-term antiplatelet therapies. It is remarkable to see how STEMI management has evolved over the last decade. With use of increasingly sophisticated stent technology, patients with STEMI are now enjoying substantial benefit by virtue of improved reperfusion with primary PCI, fewer ischemic complications, and lower rates of long-term restenosis. A goal that seemed very distant only a decade ago appears now to have been achieved," the authors write.

JAMA. 2005;293:2154-2156
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

Contact us

RxPG Online



    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)